MNPR compared with BCRX: revenue, margins and what each company keeps, and the suppliers and customers both name

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

BCRXBiocryst Pharmaceuticals Inc

Mkt capRevenueRevenue

Compare

MNPRMonopar Therapeutics

BCRXBiocryst Pharmaceuticals Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

MNPRMonopar Therapeutics

66.46▼−5.49%· post 66.45

Mkt cap$472.0MRevenue—Revenue—

BCRXBiocryst Pharmaceuticals Inc

8.25▼−2.55%· post 8.25

ClosedNov 2 '26

Mkt cap$2.2BRevenue$218MQ2 FY26Revenue$875MFY25

Compare

ClosedNov 2 '26

MNPRMonopar Therapeutics

BCRXBiocryst Pharmaceuticals Inc

66.46▼−5.49%post 66.45

Price

8.25▼−2.55%post 8.25

$472.0M

Mkt cap

$2.2B

—

Revenue

$218MQ2 FY26

—

Revenue

$875MFY25

MNPR66.46▼−5.49%vsBCRX8.25▼−2.55%ClosedNov 2 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

MNPR: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only MNPR 2

AZNAstraZenecasupplier

—NorthStarunlistedsupplier

Shared 0

No shared counterparties.

Only BCRX 1

—Specialty pharmacy providerunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

MNPR, solidBCRX, dashed